HSBC Downgrades XPeng to Hold, $10.10 Price Target

Analyst: Yuqian Ding 1 min read Reproduced verbatim
Rating
Hold
from Buy
Target
$10.10
from $27.70 (−64%)
Upside
+8%
XPEV at $9.38 today

2nd-lowest of 9 current targets on XPeng, 33% below the $15 median. HSBC has reached 60% of its year-old targets (30 scored).

HSBC and XPeng logos

What the analyst said

HSBC analyst Yuqian Ding downgraded XPeng (NYSE: XPEV) from Buy to Hold with a price target of $10.10.

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

XPEV trades at $9.38. The 9 analysts who set a target in the last 3 months range from $10 to $20, with a median of $15. This $10.10 target is 33% below the median.

12-month window: day 0 of 365, closes on November 20, 2027.

Track record

This callOpen: a 12-month target, scored on November 20, 2027, a year after the note.

Firm track recordHSBC: 60% of its 30 targets at least a year old were reached within 12 months (#29 of 29 firms). Accuracy ranking →

HSBC on XPeng

HSBC price targets on XPeng

3 calls from August 22, 2025 to November 20, 2026. The target went from $29.60 to $10.10 (−66%). The rating moved from Buy to Hold.

HSBC targetXPEV share price
  1. November 20, 2026 This noteDowngraded to Hold, target cut from $27.70 (−64%)Hold$10.10
  2. January 20, 2026Target cut from $29.60 (−6%)Buy$27.70
  3. August 22, 2025Earliest call shownBuy$29.60
Share Reddit StockTwits
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.